Background
- With the emergence of effective therapies targeting specific KRAS mutations (mt), identifying these unique KRAS mts in NSCLC has become increasingly relevant.
- Acquired KRAS mutations are a known resistance mechanism in driver mutation-positive (DM+) NSCLC.
- The incidence and diversity of these acquired alterations and whether they differ from those observed in de novo KRAS mt NSCLC is unknown.
- We aimed to characterize the distribution of KRAS mt between acquired and de novo KRAS mt NSCLC, as well as the distribution of unique KRAS mt by driver mutation.
Conclusions
- While the distribution of unique KRAS mutations did not differ significantly between DN and ACQ subgroups, acquired KRAS mutations at varying frequencies were seen across DM+ NSCLC subsets.
- The functional and immunological significance of these mutations, and their impact on clinical outcomes, warrants further investigation.